{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:43:44Z","timestamp":1762501424252,"version":"build-2065373602"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T00:00:00Z","timestamp":1683676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jctube.2023.100376","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T22:57:40Z","timestamp":1684364260000},"page":"100376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Fluoroquinolone-resistant latent tuberculosis infection: A literature review and case series of 5 patients treated with linezolid monotherapy"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3698-0613","authenticated-orcid":false,"given":"Jacob J.","family":"Baker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Nahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian K.","family":"Petroelje","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neela D.","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred A.","family":"Lardizabal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jctube.2023.100376_b0005","unstructured":"Global Tuberculosis Report 202World Health Organization. 2021."},{"issue":"3","key":"10.1016\/j.jctube.2023.100376_b0010","doi-asserted-by":"crossref","first-page":"1900655","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.jctube.2023.100376_b0015","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2016.10357","article-title":"Primary care screening and treatment for latent tuberculosis infection in adults: evidence report and systematic review for the US preventive services task force","volume":"316","author":"Kahwati","year":"2016","journal-title":"JAMA"},{"issue":"9979","key":"10.1016\/j.jctube.2023.100376_b0020","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO's new end TB strategy","volume":"385","author":"Uplekar","year":"2015","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jctube.2023.100376_b0025","doi-asserted-by":"crossref","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","article-title":"The global burden of latent tuberculosis infection: A re-estimation using mathematical modelling","volume":"13","author":"Houben","year":"2016","journal-title":"PLoS Med"},{"issue":"11","key":"10.1016\/j.jctube.2023.100376_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140881","article-title":"Tuberculosis infection in the United States: prevalence estimates from the national health and nutrition examination survey, 2011-2012","volume":"10","author":"Miramontes","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jctube.2023.100376_b0035","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/aje\/kwt246","article-title":"Estimated rate of reactivation of latent tuberculosis infection in the United States, overall and by population subgroup","volume":"179","author":"Shea","year":"2014","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.jctube.2023.100376_b0040","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1473-3099(19)30307-X","article-title":"Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling","volume":"19","author":"Knight","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jctube.2023.100376_b0045","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep, 2000. 49(Rr-6): p. 1-51."},{"issue":"1","key":"10.1016\/j.jctube.2023.100376_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"12","key":"10.1016\/j.jctube.2023.100376_b0055","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/cid\/cix208","article-title":"Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis","volume":"64","author":"Marks","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jctube.2023.100376_b0060","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.5588\/ijtld.12.0092","article-title":"Long-term follow-up of contacts exposed to multidrug-resistant tuberculosis in Victoria, Australia, 1995\u20132010","volume":"16","author":"Denholm","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"issue":"8","key":"10.1016\/j.jctube.2023.100376_b0065","doi-asserted-by":"crossref","first-page":"912","DOI":"10.5588\/ijtld.13.0028","article-title":"Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009\u20132012","volume":"18","author":"Bamrah","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"issue":"10","key":"10.1016\/j.jctube.2023.100376_b0070","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jctube.2023.100376_b0075","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee, in WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment: Module 1: prevention. 2020, World Health Organization \u00a9 World Health Organization 2020.: Geneva."},{"year":"2022","series-title":"Surveillance definitions for extensively drug resistant (XDR) and pre-XDR tuberculosis, in Dear Colleague Letters","author":"Langer","key":"10.1016\/j.jctube.2023.100376_b0080"},{"issue":"3","key":"10.1016\/j.jctube.2023.100376_b0085","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1084\/jem.123.3.469","article-title":"Microbial persistence. II. Characteristics of the sterile state of tubercle bacilli","volume":"123","author":"McCune","year":"1966","journal-title":"J Exp Med"},{"issue":"1","key":"10.1016\/j.jctube.2023.100376_b0090","first-page":"5","article-title":"The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy","volume":"53","author":"Grosset","year":"1978","journal-title":"Bull Int Union Tuberc"},{"key":"10.1016\/j.jctube.2023.100376_b0095","unstructured":"WHO Guidelines Approved by the Guidelines Review Committee, in WHO consolidated guidelines on tuberculosis: Module 4: Treatment - Drug-resistant tuberculosis treatment. 2020, World Health Organization \u00a9 World Health Organization 2020.: Geneva."},{"issue":"10","key":"10.1016\/j.jctube.2023.100376_b0100","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jctube.2023.100376_b0105","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa2119430","article-title":"Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis","volume":"387","author":"Conradie","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jctube.2023.100376_b0110","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-022-06331-8","volume":"23","author":"Berry","year":"2022","journal-title":"Trials"},{"issue":"10","key":"10.1016\/j.jctube.2023.100376_b0115","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1164\/rccm.202107-1779OC","article-title":"An All-Oral 6-Month Regimen for Multidrug-Resistant Tuberculosis: A Multicenter, Randomized Controlled Clinical Trial (the NExT Study)","volume":"205","author":"Esmail","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"10366","key":"10.1016\/j.jctube.2023.100376_b0120","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(22)02078-5","article-title":"Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial","volume":"400","author":"Goodall","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jctube.2023.100376_b0125","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ijid.2022.02.043","article-title":"Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis","volume":"124","author":"Nasiri","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jctube.2023.100376_b0130","first-page":"p. ii9-16","article-title":"Linezolid in vitro: mechanism and antibacterial spectrum","volume":"51 Suppl 2","author":"Livermore","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.jctube.2023.100376_b0135","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1128\/AAC.00414-07","article-title":"In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years","volume":"52","author":"Huang","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"10.1016\/j.jctube.2023.100376_b0140","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1128\/AAC.43.5.1189","article-title":"Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model","volume":"43","author":"Cynamon","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"issue":"16","key":"10.1016\/j.jctube.2023.100376_b0145","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jctube.2023.100376_b0150","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s15010-014-0632-2","article-title":"Linezolid in the treatment of extensively drug-resistant tuberculosis","volume":"42","author":"Zhang","year":"2014","journal-title":"Infection"},{"issue":"1","key":"10.1016\/j.jctube.2023.100376_b0155","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China","volume":"45","author":"Tang","year":"2015","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jctube.2023.100376_b0160","first-page":"603","article-title":"Systematic review and meta-analysis of the efficacy and safety of therapy with linezolid containing regimens in the treatment of multidrug-resistant and extensively drug-resistant tuberculosis","volume":"7","author":"Zhang","year":"2015","journal-title":"J Thorac Dis"},{"issue":"21","key":"10.1016\/j.jctube.2023.100376_b0165","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJM200511243532123","article-title":"Mitochondrial toxicity associated with linezolid","volume":"353","author":"Soriano","year":"2005","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jctube.2023.100376_b0170","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00221-18","article-title":"Linezolid kills acid-phase and nonreplicative-persister-phase mycobacterium tuberculosis in a hollow-fiber infection model","volume":"62","author":"Drusano","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jctube.2023.100376_b0175","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1016\/S1472-9792(08)70038-6","article-title":"The early bactericidal activity of anti-tuberculosis drugs: a literature review","volume":"88","author":"Donald","year":"2008","journal-title":"Tuberculosis (Edinb)"},{"issue":"11","key":"10.1016\/j.jctube.2023.100376_b0180","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1164\/rccm.200806-892OC","article-title":"Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis","volume":"178","author":"Dietze","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jctube.2023.100376_b0185","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/jac\/dkg262","article-title":"Intrapulmonary penetration of linezolid","volume":"51","author":"Honeybourne","year":"2003","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jctube.2023.100376_b0190","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","article-title":"Intrapulmonary pharmacokinetics of linezolid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jctube.2023.100376_b0195","doi-asserted-by":"crossref","unstructured":"EUCAST Technical Note on linezolid. Clin Microbiol Infect, 2006. 12(12): p. 1243-5.","DOI":"10.1111\/j.1469-0691.2006.01577.x"},{"issue":"4","key":"10.1016\/j.jctube.2023.100376_b0200","doi-asserted-by":"crossref","first-page":"502","DOI":"10.5588\/ijtld.10.0238","article-title":"Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis","volume":"15","author":"Sch\u00f6n","year":"2011","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"10.1016\/j.jctube.2023.100376_b0205","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/jac\/dky414","article-title":"Bedaquiline and linezolid MIC distributions and epidemiological cut-off values for Mycobacterium tuberculosis in the Latin American region","volume":"74","author":"Lopez","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"10.1016\/j.jctube.2023.100376_b0210","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/infdis\/jiaa016","article-title":"Pharmacodynamic correlates of linezolid activity and toxicity in murine models of tuberculosis","volume":"223","author":"Bigelow","year":"2021","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.jctube.2023.100376_b0215","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01174-20","article-title":"Population pharmacokinetics of linezolid in tuberculosis patients: dosing regimen simulation and target attainment analysis","volume":"64","author":"Alghamdi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jctube.2023.100376_b0220","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00751-17","article-title":"Linezolid dose that maximizes sterilizing effect while minimizing toxicity and resistance emergence for tuberculosis","volume":"61","author":"Srivastava","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.jctube.2023.100376_b0225","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3201\/eid2608.191499","article-title":"Linezolid-associated neurologic adverse events in patients with multidrug-resistant tuberculosis, France","volume":"26","author":"Jaspard","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"10.1016\/j.jctube.2023.100376_b0230","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.ebiom.2015.09.051","article-title":"Linezolid trough concentrations correlate with mitochondrial toxicity-related adverse events in the treatment of chronic extensively drug-resistant tuberculosis","volume":"2","author":"Song","year":"2015","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.jctube.2023.100376_b0235","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/jac\/dkl298","article-title":"Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis","volume":"58","author":"Park","year":"2006","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"10.1016\/j.jctube.2023.100376_b0240","doi-asserted-by":"crossref","first-page":"ofac500","DOI":"10.1093\/ofid\/ofac500","article-title":"Low-dose linezolid for treatment of patients with multidrug-resistant tuberculosis","volume":"9","author":"Mase","year":"2022","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.jctube.2023.100376_b0245","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1183\/09031936.05.00006205","article-title":"High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis","volume":"26","author":"Younossian","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jctube.2023.100376_b0250","unstructured":"Clinical programs and policy manual: New York City Department of Health and Mental Hygiene Bureau of Tuberculosis Control 2022. 2022."},{"issue":"1","key":"10.1016\/j.jctube.2023.100376_b0255","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-033945","article-title":"Levofloxacin versus placebo for the treatment of latent tuberculosis among contacts of patients with multidrug-resistant tuberculosis (the VQUIN MDR trial): a protocol for a randomised controlled trial","volume":"10","author":"Fox","year":"2020","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jctube.2023.100376_b0260","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-018-3070-0","article-title":"Levofloxacin versus placebo for the prevention of tuberculosis disease in child contacts of multidrug-resistant tuberculosis: study protocol for a phase III cluster randomised controlled trial (TB-CHAMP)","volume":"19","author":"Seddon","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.jctube.2023.100376_b0265","doi-asserted-by":"crossref","first-page":"m216","DOI":"10.1136\/bmj.m216","article-title":"Current and future treatments for tuberculosis","volume":"368","author":"Lee","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jctube.2023.100376_b0270","article-title":"The pipeline of new molecules and regimens against drug-resistant tuberculosis","volume":"25","author":"Black","year":"2021","journal-title":"J Clin Tubercul Other Mycobact Diseases"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579423000323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579423000323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:38:54Z","timestamp":1762501134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579423000323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":54,"alternative-id":["S2405579423000323"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2023.100376","relation":{},"ISSN":["2405-5794"],"issn-type":[{"type":"print","value":"2405-5794"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fluoroquinolone-resistant latent tuberculosis infection: A literature review and case series of 5 patients treated with linezolid monotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2023.100376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100376"}}